This website is for UK healthcare professionals and UK healthcare decision makers only

Reporting adverse events
A
A
Prescribing information for:

Ferinject 
(ferric carboxymaltose)

Kapruvia ▼
(difelikefalin)

Tavneos ▼
(avacopan)

Veltassa 
(patiromer)

Venofer 
(iron sucrose)

FERINJECT®
(ferric carboxymaltose)

KAPRUVIA®(difelikefalin)

TAVNEOS®(avacopan)

VELTASSA®
(patiromer)

WEBINARS
AND EVENTS

2023 FOCUSED UPDATE TO
THE 2021 ESC HF GUIDELINES

Find out how intravenous iron supplementation is recommended to treat iron deficiency in patients with HF

FERINJECT, FOR IRON DEFICIENCY
IN PATIENTS WITH HF

Explore the AFFIRM-AHF study which investigated the use of Ferinject in patients with iron deficiency and HF

FIND-CKD - Ferinject DOSED TO achieve high ferritin levels in ND-CKD

Explore the results of the FIND-CKD study to see how Ferinject may lead to more effective management of iron deficiency anaemia

IRON DEFICIENCY IN SURGICAL
PATIENTS

Explore the data and discover the impact of anaemia and iron deficiency on patients undergoing surgery

FERINJECT, LICENSED FOR PAEDIATRIC PATIENTS

Read more about Ferinject use in paediatric patients. Ferinject is approved for the treatment of iron deficiency in appropriate patients aged 1 year and older

FERINJECT, A NANOMEDICINE FOR IRON DEFICIENCY

Learn how nanomedicines, like Ferinject, are manufactured to elicit their novel pharmacological properties

CKD, chronic kidney disease; ESC, European Society of Cardiology; HF, heart failure; ND-CKD, non-dialysis chronic kidney disease.

 

 

 

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Vifor Pharma UK Ltd. (Tel 01276 853633). Email: medicalinfo_UK@viforpharma.com
More Resources

KAPRUVIA®

Resources

Webinars and events

Resources

You are now heading to a third-party website that we do
not operate. We are not responsible for the content of the
third-party website. You are advised to review its privacy policy
as it may differ from ours.

 

Are you sure you want to leave?

Confirm

Cancel

Report adverse events in the UK:

Adverse events should be reported. Reporting forms and information for United Kingdom can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Vifor Pharma Ltd. Tel: +44 1276 853633. E-mail: medicalInfo_UK@viforpharma.com